EYPT250117C25000
- 0.10
- 0.000.00%
EyePoint Pharmaceuticals Newsroom
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $22
EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
EyePoint Pharmaceuticals Analyst Ratings
Express News | EyePoint Pharmaceuticals Inc - Topline Data for Phase 3 Pivotal Program Expected in 2026
Express News | EyePoint Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of Duravyu™ for the Treatment of Wet Age-Related Macular Degeneration
EyePoint Pharmaceuticals Poised for Growth With Promising DME Treatment Duravyu
Some EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shareholders Look For Exit As Shares Take 27% Pounding
Selling EyePoint Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Express News | EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?
Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $33
JonesTrading Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $22
EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
EyePoint Pharmaceuticals Price Target Cut to $22.00/Share From $30.00 by HC Wainwright & Co.
Express News | Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $33
EyePoint Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
TD Cowen Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $20
EyePoint Pharmaceuticals: Advancements in Clinical Trials and Promising Interim Data Boost Buy Rating